[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"liquid-biopsy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:liquid-biopsy":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,43,67,93,120,142,174,197,219,239,261,287,313,348,376,404],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100538206","french-assessment-of-mrd-by-liquid-biopsies-in-stage-iii-crc-patients-frenchmrdcrc-100538206",false,"NCT06287814","French Assessment of MRD by Liquid Biopsies in Stage III CRC Patients (FRENCH.MRD.CRC)","French Assessment of Minimal Residual Disease by Liquid Biopsies in Stage III Colorectal Patients","FRENCH.MRD.CRC PART I Inclusion criteria\n\n* Colon or rectal cancer, clinical tumor stage I-III.\n* Patient 18 years or older.\n* Scheduled for curative intent resection surgery (including \"compromised\" curative resections).\n\nExclusion criteria\n\n* Hereditary colorectal cancer linked to familial colonic polyposis or Lynch syndrome.\n* Verified distant metastases.\n* Malignant colorectal polyps diagnosed after polypectomy.\n* Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude), inability to return for subsequent visits) and\u002For otherwise considered by the Investigator to be unlikely to complete the study.\n* Pregnant or nursing woman, or in childbearing age and not willing to use contraception\n* Protected and vulnerable adult\n* Not covered by Health insurance\n* Patient unable to understand and sign written informed consent.\n\nFRENCH.MRD.CRC PART II Inclusion criteria\n\n* Participation in FRENCH.MRD.CRC part 1 - SURGERY\n* Colorectal cancer, UICC stage III\n* Has received curative-intent resection and is a candidate for adjuvant chemotherapy (3- or 6-months regime) Exclusion criteria\n* Inflammatory bowel disease (Crohn's disease or ulcerative colitis) related colon cancer\n* Not treated with adjuvant chemotherapy despite indication (incomplete treatment not included)\n* Treated with neoadjuvant chemo-radiation therapy\n* Synchronous colorectal and non-colorectal cancer diagnosed per operative (except skin cancer other than melanoma)\n* Other cancers (excluding colorectal cancer or skin cancer other than melanoma) within 3 years from eligibility screening\n* Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude), inability to return for subsequent visits) and\u002For otherwise considered by the Investigator to be unlikely to complete the study","ALL","18 Years",{"count":19,"type":20},70,"ESTIMATED","OBSERVATIONAL","Improving personalized cancer treatments and finding the best strategies to treat each patient relies on using new diagnostic technologies. Currently, for colorectal cancer, the methods used to decide who gets additional post-surgery treatment are suboptimal. Some patients get too much treatment, while others do not get enough.\n\nThere is a new way to explore if there is any cancer left in a patient's body using circulating tumor DNA (ctDNA) detected in blood samples. This can help decide who needs more treatment after surgery. Even though many tests have been developed, it has yet to be determined which test performs best at relevant time points.\n\nThe GUIDE.MRD consortium is a group of experts, including scientists, technology, and pharmaceutical companies. The consortium is working on creating a reliable standard for the ctDNA tests, validating their clinical utility, and collecting data to help decide on the best treatment for each patient.\n\nFRENCH-MRD-CRC is the French study of the european GUIDE.MRD project.",[24,25,26,27],"Colorectal Cancer","Stage III Colon Cancer","Minimal Residual Disease","Liquid Biopsy",[29,26,27],"Stage III colorectal cancer","RECRUITING","2026-06-17",{"date":33,"type":34},"2026-06-22","ACTUAL",{"date":36,"type":34},"2024-04-11",{"date":38,"type":20},"2033-10-31",{"name":40,"class":41},"University Hospital, Montpellier","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":52,"conditions":53,"keywords":57,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":60,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},"100538199","french-assessment-of-mrd-by-liquid-biopsies-in-colorectal-with-liver-metastasis-patients-frenchmrdcrlm-100538199","NCT06287723","French Assessment of MRD by Liquid Biopsies in Colorectal With Liver Metastasis Patients (FRENCH.MRD.CRLM)","French Assessment of Minimal Residual Disease by Liquid Biopsies in Colorectal With Liver Metastasis Patients","Inclusion Criteria:\n\n* Patient 18 years or older.\n* Colorectal cancer liver metastasis or metastases, according to the assessment of the MDT.\n* Metachronous and synchronous metastases will be included, as long as treatment intention of metastases resection is curative. In case of rare instances, where the liver metastases is removed before surgery of the primary tumor, postOP ctDNA is collected when the patient is considered completely tumor-free, i.e. after complete surgery of both the liver metastases and the primary tumor.\n* Treatment is planned with curative intent (patients treated with RFA can be included, BUT in these cases a tissue sample from the primary CRC tumor is a requisite)\n\nExclusion Criteria:\n\n* Hereditary colorectal cancer linked to familial colonic polyposis or Lynch syndrome.\n* Extrahepatic metastases\n* Malignant colorectal polyps diagnosed after polypectomy.\n* Synchronous colorectal and non-colorectal cancer diagnosed per operative (except skin cancer other than melanoma)\n* Other cancers (excluding colorectal cancer or skin cancer other than melanoma) within 3 years from eligibility screening\n* Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude), inability to return for subsequent visits) and\u002For otherwise considered by the Investigator to be unlikely to complete the study.\n* Liver cirrhosis\n* CRLM intervention\u002Fsurgery cannot be\u002Fwas not performed with curative intent\n* No tumor tissue available (preferably CRLM lesion, or alternatively primary tumor)\n* Pregnant or nursing woman, or in childbearing age and not willing to use contraception\n* Protected and vulnerable adult\n* Not covered by Health insurance\n* Patient unable to understand and sign written informed consent.",{"count":51,"type":20},30,"Improving personalized cancer treatments and finding the best strategies to treat each patient relies on using new diagnostic technologies. Currently, for colorectal cancer, the methods used to decide who gets additional post-surgery treatment are suboptimal. Some patients get too much treatment, while others do not get enough.\n\nThere is a new way to explore if there is any cancer left in a patient's body using circulating tumor DNA (ctDNA) detected in blood samples. This can help decide who needs more treatment after surgery. Even though many tests have been developed, it has yet to be determined which test performs best at relevant time points.\n\nThe GUIDE.MRD consortium is a group of experts, including scientists, technology, and pharmaceutical companies. The consortium is working on creating a reliable standard for the ctDNA tests, validating their clinical utility, and collecting data to help decide on the best treatment for each patient.\n\nFRENCH.MRD.CRLM is the French study and part of the european GUIDE.MRD project.",[24,54,55,26,27,56],"Liver Metastases","Stage IV Colorectal Cancer","ctDNA",[58,26,59],"Stage IV colorectal cancer","Liquid biopsy",{"date":33,"type":34},{"date":62,"type":34},"2024-04-15",{"date":64,"type":20},"2029-04-15",{"name":40,"class":41},2,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":92},"100629494","phase-2-urinary-tumor-dna-guided-systemic-immunotherapy-for-unresectable-very-high-risk-non-muscle-invasive-bladder-cancer-100629494","NCT07475403","Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer","A Prospective Study of Urinary Tumor DNA-Guided Systemic Immunotherapy in Patients With Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Histologically confirmed non-muscle-invasive urothelial carcinoma of the bladder classified as very-high-risk (VHR) according to EAU 2025 guideline criteria.\n3. Disease considered unresectable by the investigator and multidisciplinary team, defined as complete tumor eradication by standard transurethral resection of bladder tumor (TURBT) being not feasible or unlikely to achieve adequate local control.\n4. Patients who are ineligible or refuse for radical cystectomy, after discussion with the treating team.\n5. At least one measurable or evaluable bladder lesion\u002Fdocumented residual disease suitable for response assessment by cystoscopy, TURBT\u002Fbiopsy, pathology, urine cytology, and urinary tumor DNA (utDNA) testing.\n6. ECOG performance status 0-2.\n7. Adequate organ function, including:\n\n   Hematologic function: Absolute neutrophil count ≥1.5 × 10⁹\u002FL, Platelet count ≥100 × 10⁹\u002FL, Hemoglobin ≥9 g\u002FdL Hepatic function: Total bilirubin ≤1.5 × ULN, AST ≤2.5 × ULN, ALT ≤2.5 × ULN Renal function: Serum creatinine ≤1.5 × ULN or Creatinine clearance ≥60 mL\u002Fmin.\n8. Ability to provide urine samples for utDNA testing and urine cytology during treatment and follow-up.\n\nExclusion Criteria:\n\n1. Muscle-invasive bladder cancer (≥T2), locally advanced unresectable invasive disease beyond NMIBC, or metastatic urothelial carcinoma at baseline.\n2. Histology showing predominant or pure non-urothelial carcinoma of the bladder that, in the investigator's judgment, would make the patient unsuitable for this protocol.\n3. Prior treatment with immune.\n4. Active autoimmune disease or history of autoimmune disease requiring systemic immunosuppressive treatment and considered incompatible with immune checkpoint inhibitor therapy.\n5. Ongoing systemic immunosuppressive therapy exceeding protocol-allowed doses.\n\n7\\. Active uncontrolled infection, including uncontrolled urinary tract infection, that would interfere with study treatment or response assessment.\n\n8\\. Any medical condition that would preclude safe administration of systemic immunotherapy or protocol-required cystoscopy\u002FTURBT\u002Fbiopsy, in the investigator's judgment.\n\n9\\. Concurrent other malignancy. 10. Pregnant or breastfeeding women. 11. Inability to comply with protocol procedures or follow-up.",{"count":75,"type":20},53,"INTERVENTIONAL",[78],"PHASE2","This study evaluates whether urinary tumor DNA (utDNA) testing, together with clinical, pathologic, and radiographic assessment, can help guide treatment discontinuation and active surveillance in patients with unresectable very-high-risk non-muscle-invasive bladder cancer (VHR NMIBC) treated with bladder-sparing systemic immunotherapy.\n\nParticipants receive systemic immune checkpoint inhibitor-based therapy every 3 weeks for an initial 3 cycles. Initial response assessment is performed using transurethral resection of bladder tumor (TURBT) and chest and abdominopelvic computed tomography (CT). Participants without progression to muscle-invasive, regional nodal, or distant metastatic disease then undergo post-TURBT urine cytology and urinary tumor DNA (utDNA) testing. Participants with both negative urine cytology and negative utDNA results receive an additional 3 cycles of systemic immunotherapy.\n\nAfter the additional treatment, participants undergo repeat evaluation using cystoscopy with biopsy, urine cytology, utDNA testing, and chest and abdominopelvic CT. Participants with negative findings on cystoscopic biopsy, urine cytology, and utDNA testing, and without radiographic evidence of nodal or distant metastatic disease, discontinue systemic immunotherapy and enter an active surveillance phase with regular follow-up monitoring. Participants who do not meet these criteria continue further clinical management and follow-up according to institutional practice.\n\nThe study aims to determine whether a shortened duration of systemic immunotherapy guided by integrated molecular, clinical, pathologic, and radiographic response assessment can maintain favorable oncologic outcomes while reducing unnecessary treatment exposure in this high-risk population.",[81,27,82],"Bladder Cancer","Immunotherapy","2026-05-21",{"date":85,"type":34},"2026-05-26",{"date":87,"type":34},"2026-03-16",{"date":89,"type":20},"2029-04-01",{"name":91,"class":41},"Tianjin Medical University Second Hospital",3,{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":76,"phases":102,"briefSummary":104,"conditions":105,"keywords":107,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":119},"100607367","guiding-value-of-urinary-tumor-dna-testing-in-repeat-transurethral-resection-of-non-muscle-invasive-bladder-cancer-100607367","NCT07187635","Guiding Value of Urinary Tumor DNA Testing in Repeat Transurethral Resection of Non-Muscle-Invasive Bladder Cancer","The Guiding Value of Urinary Tumor DNA Testing in Repeat Transurethral Resection of Non-Muscle-Invasive Bladder Cancer: An Open-Label, Randomized Controlled, Multi-Center Clinical Study (Truce-LB01)","Inclusion Criteria:\n\nParticipants must meet all of the following criteria to be eligible for the study:\n\n1. Male or female, aged 18 years or older.\n2. Histologically confirmed non-muscle-invasive bladder tumor, with no evidence of muscle-invasive bladder cancer or metastatic disease.\n3. Histologically confirmed urothelial carcinoma of the bladder or bladder tumor with urothelial carcinoma as the predominant component (\\>50%).\n4. At least one of the following conditions:\n\n   1. Incomplete initial transurethral resection of bladder tumor (TURBT) or suspected incomplete resection.\n   2. Absence of detrusor muscle in the initial TURBT pathological specimen (except for low-grade Ta stage tumors or carcinoma in situ \\[CIS\\]).\n   3. T1 stage tumor.\n5. Willingness to provide a 50 mL urine sample between 2-6 weeks after the initial TURBT and prior to re-TURBT.\n6. Willingness to provide tumor tissue samples for pathological examination.\n7. Willingness to undergo genetic testing required for the trial.\n\nExclusion Criteria:\n\n1. Contraindications to transurethral resection of bladder tumor (TURBT).\n2. Concurrent malignancy of the upper urinary tract (ureter or renal pelvis).",{"count":101,"type":20},196,[103],"NA","Non-muscle-invasive bladder cancer (NMIBC) accounts for approximately 75% of newly diagnosed bladder cancers and is characterized by a high risk of recurrence and progression. Current guidelines recommend that patients with stage T1 NMIBC undergo a second transurethral resection of bladder tumor (re-TURBT) within 2-6 weeks after the initial surgery to remove residual tumor, confirm staging, and obtain additional pathological information. However, the benefits of routine re-TURBT for all high-risk patients remain controversial, as many patients may not have residual disease, while the procedure carries surgical and anesthetic risks, physical and psychological burden, and additional healthcare costs.\n\nUrine tumor DNA (utDNA) refers to DNA fragments shed by tumor cells into urine. It can be detected using molecular assays with high sensitivity and specificity, offering a non-invasive method for bladder cancer diagnosis and surveillance. Previous studies have shown that positive utDNA results after initial TURBT may be associated with residual disease and higher recurrence risk.\n\nThis multicenter, randomized controlled trial aims to evaluate whether utDNA testing can accurately identify NMIBC patients who are most likely to benefit from re-TURBT, thereby guiding the decision to perform the procedure. The goal is to optimize patient selection for re-TURBT, reduce unnecessary surgeries, and improve patient quality of life while maintaining oncologic safety.",[81,27,106],"Repeat Transurethral Resection of Bladder Tumor",[108,109,110],"bladder cancer","liquid biopsy","second transurethral resection of bladder tumor","2026-05-06",{"date":113,"type":34},"2026-05-11",{"date":115,"type":34},"2025-09-28",{"date":117,"type":20},"2027-11-01",{"name":91,"class":41},6,{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":76,"phases":129,"briefSummary":130,"conditions":131,"keywords":133,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":136,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":140,"locationsCount":141},"100606796","guiding-value-of-urinary-tumor-dna-testing-in-cystoscopy-for-high-riskvery-high-risk-non-muscle-invasive-bladder-cancer-100606796","NCT07180212","Guiding Value of Urinary Tumor DNA Testing in Cystoscopy for High-Risk\u002FVery High-Risk Non-Muscle-Invasive Bladder Cancer","The Guiding Value of Urinary Tumor DNA Testing in Cystoscopy for High-Risk\u002FVery High-Risk Non-Muscle-Invasive Bladder Cancer: An Open-Label, Randomized Controlled, Multicenter Clinical Study (Truce-LB02)","Inclusion Criteria:\n\n1. Male or female participants aged 18 years or older.\n2. Histologically confirmed high-risk or very high-risk non-muscle-invasive urothelial carcinoma (NMIBC) of the bladder, as defined by the EAU 2025 NMIBC guidelines, or bladder tumors in which high-risk\u002Fvery high-risk NMIBC constitutes more than 50% of the pathological composition, diagnosed within the past 2 years, with no evidence of muscle-invasive bladder cancer or metastatic disease.\n3. Prior to enrollment, participants must have undergone either:\n\nA.Second transurethral resection of bladder tumor (re-TURBT), or B.Complete initial TURBT with negative basal margins, peripheral margins, and multiple site biopsies, with pathological specimens including detrusor muscle and showing no residual tumor, and negative urine cytology at 2 weeks post-surgery.\n\nExclusion Criteria:\n\n1.History of upper urinary tract malignancy (ureter or renal pelvis) within the past 5 years or concurrent diagnosis of upper urinary tract urothelial carcinoma.",{"count":128,"type":20},360,[103],"Non-muscle-invasive bladder cancer (NMIBC) is usually treated with surgery to remove the tumor (transurethral resection of bladder tumor, or TURBT), often followed by bladder-instilled medications to reduce the chance of the cancer coming back. Even with this treatment, high-grade NMIBC can return or progress, so patients need regular check-ups, usually with cystoscopy (a camera examination of the bladder) and urine cytology.\n\nCystoscopy is effective but invasive, can cause discomfort, and carries risks such as infection and bleeding. This makes follow-up costly and sometimes burdensome for patients.\n\nThis study is testing whether a urine tumor DNA (utDNA) test - a type of \"liquid biopsy\" that detects cancer-related DNA changes in urine - can help guide the timing of cystoscopy for people with high-risk or very high-risk NMIBC. utDNA testing is non-invasive and has shown high accuracy in detecting bladder cancer, sometimes spotting signs of recurrence earlier than standard methods.\n\nBy combining utDNA testing with cystoscopy, we hope to safely reduce the number of unnecessary cystoscopies without missing cancer recurrences. The study will evaluate whether this approach can make bladder cancer follow-up more comfortable, more precise, and more efficient.",[81,27,132],"Cystoscopy",[108,109,134,135],"cystoscopy","urine tumor DNA",{"date":113,"type":34},{"date":138,"type":34},"2025-09-20",{"date":117,"type":20},{"name":91,"class":41},8,{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":150,"minAge":17,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":153,"conditions":154,"keywords":161,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":173},"100635520","plasma-exosomal-rna-signature-for-prostate-cancer-bone-metastasis-100635520","NCT07553754","Plasma Exosomal RNA Signature for Prostate Cancer Bone Metastasis","Plasma Exosomal RNA Signature for Predicting PSMA PET-Defined Bone Metastasis in Prostate Cancer: A Prospective, Multicenter Discovery, Development, and Validation Study","EXO-MET","Inclusion Criteria\n\n1. Patients with histologically confirmed prostate cancer who are scheduled to undergo baseline PSMA PET imaging.\n2. Patients who undergo PSMA PET imaging prior to any prostate cancer-related treatment (including androgen deprivation therapy, radiotherapy, or surgery).\n3. Patients who provide blood samples for plasma exosomal RNA analysis collected prior to any treatment AND prior to prostate biopsy (if applicable).\n\n   Whole blood samples (approximately 10 mL) will be collected in EDTA tubes at this specified time point. Samples will be processed within 2 hours to obtain plasma and stored at -80°C until analysis.This timing ensures circulating exosomal RNA profiles reflect tumor biology without biopsy-induced contamination.\n4. Patients who are willing to undergo prostate biopsy if clinically indicated (biopsy performed after blood collection).\n5. Patients who provide written informed consent to participate in the study.\n6. Age ≥18 years.\n\nExclusion Criteria\n\n1. Patients who have received any prior prostate cancer-related treatment before the baseline PSMA PET scan (including hormonal therapy, radiotherapy, chemotherapy, or surgery).\n2. Patients whose blood samples were collected after prostate biopsy.\n3. Patients with a history of other active malignancies within the past two years (excluding non-melanoma skin cancer).\n4. Patients with inadequate blood sample quality or quantity for exosomal RNA extraction and analysis (e.g., hemolysis, insufficient volume \\\u003C8 mL).\n5. Patients with severe comorbidities or conditions that, in the judgment of the investigator, could interfere with study compliance or pose significant risk.","MALE",{"count":152,"type":20},1000,"Brief Summary:\n\nThis prospective, multicenter study aims to discover, develop, and validate a plasma exosomal RNA-based signature as a rule-out test for predicting bone metastasis in prostate cancer, using baseline treatment-naïve PSMA PET as the gold standard. The study is designed in four sequential phases:\n\nPhase 1 (Discovery, n=250): High-throughput sequencing of plasma exosomal RNAs to identify differentially expressed candidate RNAs.\n\nPhase 2 (Model Development, n=300): Digital droplet PCR (ddPCR) analysis of candidates in an independent cohort to construct and lock the final multi-RNA predictive signature using appropriate machine learning methods.\n\nPhase 3 (Internal Validation, n=300): Independent validation of the locked signature in a consecutive cohort reflecting natural disease prevalence.\n\nPhase 4 (External Validation, n=150): Final independent validation in a multi-center cohort enriched for bone metastasis.\n\nPrimary Outcome:\n\nTo evaluate the diagnostic performance of the signature as a rule-out test for PSMA PET-defined bone metastasis. The primary performance metrics are:\n\nSensitivity, with a prespecified target of ≥95% (to ensure minimal false negatives).\n\nSpecificity at the threshold that achieves the ≥95% sensitivity. A specificity of ≥30% will be considered supportive of clinical utility. A specificity of ≥30% (or a lower bound of the 95% confidence interval exceeding 20%) will be considered supportive of clinical utility.\n\nNeed:\n\nCurrent biomarkers lack sensitivity and specificity for early detection of bone metastasis. More importantly, existing tools lack adequate negative predictive value to safely rule out bone metastasis in low-risk patients, leading to over-imaging or delayed detection. There is an urgent need for a non-invasive rule-out test to safely defer PSMA PET\u002FCT in very-low-risk patients. Plasma exosomal RNAs offer a promising liquid biopsy approach, but prospective multicenter studies with rigorous validation are lacking.\n\nSecondary Outcomes:\n\n1. Secondary metrics include negative predictive value (NPV), positive predictive value (PPV), area under the ROC curve (AUC), calibration, and decision curve analysis.\n2. Correlation between exosomal RNA levels and number of bone metastatic lesions (PSMA PET).\n3. Association with PSA, PSMA PET SUVmax, and MRI findings.\n4. Tissue-plasma correlation to confirm tumor origin (exploratory).\n5. Mechanistic exploration of key candidates via in vitro\u002Fin vivo assays (exploratory).\n6. Subgroup analyses by hormone sensitivity, metastatic pattern, Gleason grade (exploratory).\n\nInclusion Criteria:\n\n1. Histologically confirmed prostate cancer scheduled for baseline PSMA PET.\n2. PSMA PET performed prior to any prostate cancer-related treatment.\n3. Blood samples collected prior to any treatment AND prior to prostate biopsy.\n4. Willing to undergo prostate biopsy if clinically indicated (after blood collection).\n5. Written informed consent.\n6. Age ≥18 years.\n\nExclusion Criteria:\n\n1. Any prior prostate cancer treatment before baseline PSMA PET.\n2. Blood samples collected after prostate biopsy.\n3. Other active malignancy within past two years (excluding non-melanoma skin cancer).\n4. Inadequate blood sample quality or quantity.\n5. Severe comorbidities interfering with study conduct.",[155,156,157,27,158,159,160],"Prostate Cancer (Diagnosis)","Bone Metastasis","PSMA PET","Exosomal RNA","Biomarker Discovery and Validation","Treament-naive",[162,156,157,27,158,163],"Prostate Cancer","Predictive Signature","2026-04-20",{"date":166,"type":34},"2026-04-28",{"date":168,"type":34},"2026-03-12",{"date":170,"type":20},"2027-12-31",{"name":172,"class":41},"Xijing Hospital",9,{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":180,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":182,"conditions":183,"keywords":4,"overallStatus":187,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":42},"100628858","a-study-to-evaluate-the-safety-and-efficacy-of-intracranial-venous-blood-sampling-for-liquid-biopsy-in-the-diagnosis-of-brain-cancers-100628858","NCT07467109","A Study to Evaluate the Safety and Efficacy of Intracranial Venous Blood Sampling for Liquid Biopsy in the Diagnosis of Brain Cancers","Eligibility Criteria\n\n1. Subjects over the age of 18 with suspected or confirmed, recently diagnosed, previously treated or recurrent high-grade glioma (WHO grade III and IV) in whom a diagnostic cerebral Angiogram is indicated as standard of care may be approached for participation in this study.\n2. Subjects are eligible if review of relevant intracranial cerebrovascular anatomy by cross sectional imaging such as CTA head and MRI brain, is deemed suitable for endovascular intracranial venous sampling.\n3. For subjects with suspected or recently diagnosed glioma, subjects are eligible if they have or are scheduled to undergo surgical biopsy or surgical resection of the tumor within 4 weeks (+\u002F- 1 week) of the planned liquid biopsy.\n4. For subjects with previously treated or recurrent glioma in whom tissue diagnosis and molecular profiling had been previously performed on surgical specimens at any time in the past, a planned surgical biopsy\u002Fresection is desirable but not necessary for inclusion in the study.\n\n   • Ability to understand and the willingness to sign an informed consent document.\n5. For participants with known history of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy within 6 months, if indicated.\n6. Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. For participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load within 6 months.\n7. Participants with a known history of human immunodeficiency virus (HIV on effective antiretroviral therapy with undetectable viral load within 6 months are eligible for this trial.\n8. Karnofsky Performance Scale ≥ 60%\n9. Participants must have adequate organ and marrow function as defined below:\n\nhemoglobin ≥ 7mg\u002FdL absolute neutrophil count ≥ 1,000\u002FmcL platelets ≥ 100,000\u002FmcL International Normalized Ratio ≤ 1.7 AST(SGOT)\u002FALT(SGPT) ≤3 × institutional ULN creatinine ≤ 1.5mg\u002FdL\n\nExclusion Criteria\n\n1. Subjects with suspected glioma or other brain cancers who do not have a tissue diagnosis and no surgical biopsy or resection is anticipated.\n2. Subjects in whom diagnostic cerebral angiogram is contra-indicated defined as:\n\n   * Severe contrast allergy\n   * Acute\u002Fchronic renal dysfunction with eGFR \\\u003C 45 ml\u002Fmin and Cr ≤ 1.5 mg\u002FdL\n3. For participants undergoing surgery, refractory coagulopathy or thrombocytopenia which cannot be corrected defined as:\n\n   * Platelets ≤100,000\u002FmcL\n   * International Normalized Ratio ≤ 1.7\n4. Subjects that have a known high risk in monitored anesthetic care or general anesthesia assessed by the treating physician.\n5. Anatomic considerations: based on cross-sectional imaging such as CT angiogram of the head and neck, the anatomy for arterial and venous vascular access is deemed unsuitable for endovascular access such as high-grade carotid artery stenosis, absent or occluded internal jugular veins, sigmoid sinuses and\u002For transverse sinuses.\n6. Participants with clinical cerebral edema evidenced from altered mental status\n7. Pregnant women due to risk of radiation exposure to the fetus, as determined by pregnancy urinalysis or serum analysis test during screening.\n8. Subjects with psychiatric illness\u002Fsocial situations that would limit compliance with study requirements at the physician's discretion.",{"count":181,"type":20},20,"To learn if drawing blood directly from veins inside the brain is safe and can effectively provide the same kind of detailed information about high-grade glioma as traditional surgical biopsy.",[184,185,27,186],"Intracranial Venous Blood","Brain Cancers","Evaluate the Safety","NOT_YET_RECRUITING","2026-03-18",{"date":190,"type":34},"2026-03-19",{"date":192,"type":20},"2026-08-19",{"date":194,"type":20},"2029-05-01",{"name":196,"class":41},"M.D. Anderson Cancer Center",{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":206,"conditions":207,"keywords":208,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":66},"100602981","the-guiding-value-of-liquid-biopsy-based-on-urinary-tumor-dnarna-in-the-second-transurethral-resection-of-high-risk-non-muscle-invasive-bladder-cancer-100602981","NCT07130578","The Guiding Value of Liquid Biopsy Based on Urinary Tumor DNA\u002FRNA in the Second Transurethral Resection of High-risk Non-muscle Invasive Bladder Cancer","Truce-LB00:The Guiding Value of Liquid Biopsy Based on Urinary Tumor DNA\u002FRNA in the Second Transurethral Resection of High-risk Non-muscle Invasive Bladder Cancer: An Open-Label, Observational, Single-Center Clinical Study","Inclusion Criteria:\n\nParticipants must meet all of the following criteria to be eligible for the study:\n\n1. Male or female, aged 18 years or older.\n2. Histologically confirmed non-muscle-invasive bladder tumor, with no evidence of muscle-invasive bladder cancer or metastatic disease.\n3. Histologically confirmed urothelial carcinoma of the bladder or bladder tumor with urothelial carcinoma as the predominant component (\\>50%).\n4. At least one of the following conditions:\n\n   1. Incomplete initial transurethral resection of bladder tumor (TURBT) or suspected incomplete resection.\n   2. Absence of detrusor muscle in the initial TURBT pathological specimen (except for low-grade Ta stage tumors or carcinoma in situ \\[CIS\\]).\n   3. T1 stage tumor.\n5. Willingness to provide a 50 mL urine sample between 2-6 weeks after the initial TURBT and prior to re-TURBT.\n6. Willingness to provide tumor tissue samples for pathological examination.\n7. Willingness to undergo genetic testing required for the trial.\n8. Voluntarily agrees to participate in the study, has signed informed consent, demonstrates good compliance, and is willing to complete study follow-up.\n\nExclusion Criteria:\n\n1. Contraindications to transurethral resection of bladder tumor (TURBT).\n2. Concurrent malignancy of the upper urinary tract (ureter or renal pelvis).",{"count":205,"type":20},60,"High-risk non-muscle-invasive bladder cancer (NMIBC) carries a substantial risk of residual disease after initial transurethral resection of bladder tumor (TURBT). Current guidelines recommend a second TURBT (re-TURBT) within 2-6 weeks for patients with stage T1 disease to remove residual tumor, confirm staging, and obtain additional pathological information. However, the actual survival benefit of routine re-TURBT for all high-risk patients remains debated, and the procedure may pose surgical risks, increase healthcare costs, and impact patient quality of life.\n\nUrine tumor DNA (utDNA) and urine tumor RNA (utRNA) are molecular biomarkers detectable through non-invasive \"liquid biopsy\" methods. In urothelial carcinoma, tumor-derived nucleic acids can be shed into urine, where they can be detected with high sensitivity and specificity. These biomarkers may help identify patients most likely to harbor residual disease after initial TURBT, and thus most likely to benefit from re-TURBT.\n\nThis prospective, open-label, observational, single-center study aims to evaluate the clinical value of utDNA\u002FutRNA testing in guiding re-TURBT for patients with high-risk NMIBC. The study will assess whether molecular urine testing can improve patient selection for re-TURBT, potentially reducing unnecessary procedures while maintaining oncological safety.",[81,27],[81,27,209,210],"NMIBC","re-TURBT","2026-03-01",{"date":213,"type":34},"2026-03-03",{"date":215,"type":34},"2025-09-01",{"date":217,"type":20},"2027-05-01",{"name":91,"class":41},{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":225,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":227,"conditions":228,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":42},"100626889","using-liquid-biopsy-testing-to-identify-monitor-predict-recurrence-in-urothelial-carcinoma-100626889","NCT07441499","Using Liquid Biopsy Testing to Identify, Monitor, Predict Recurrence in Urothelial Carcinoma","Inclusion Criteria:\n\n* Suspected or histologically confirmed urothelial carcinoma\n\nExclusion Criteria:\n\n* History of or concurrent active malignancy other than urothelial carcinoma",{"count":226,"type":20},300,"Application of Multi-Component Liquid Biopsy (ctDNA, utDNA, Exosomes, and Protein Biomarkers in Blood and Urine) for Auxiliary Diagnosis, Therapeutic Response Evaluation, and Recurrence Monitoring in Urothelial Carcinoma",[229,230,27],"Urothelial Carcinoma (UC)","Bladder (Urothelial, Transitional Cell) Cancer","2026-02-27",{"date":233,"type":34},"2026-03-02",{"date":235,"type":20},"2026-03",{"date":237,"type":20},"2029-01-01",{"name":91,"class":41},{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":4,"eligibilityCriteria":245,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":246,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":248,"conditions":249,"keywords":252,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":42},"100538201","french-assessment-of-mrd-by-liquid-biopsies-in-pdac-patients-frenchmrdpdac-100538201","NCT06287749","French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)","French Assessment of Minimal Residual Disease by Liquid Biopsies in Pancreatic Ductal Adenocarcinoma Patients","Inclusion Criteria:\n\n* Pancreatic ductal adenocarcinoma, according to the assessment of the MDT.\n* Age 18 years or older.\n* Scheduled for curative intent surgical resection.\n\nExclusion Criteria:\n\n* Hereditary pancreatic cancer.\n* Verified distant metastases.\n* Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude), inability to return for subsequent visits and\u002For otherwise considered by the Investigator to be unlikely to complete the study.\n* Other cancers (excluding prior pancreatic cancer or skin cancer other than melanoma) within 3 years from eligibility screening.\n* Pregnant or nursing woman, or in childbearing age and not willing to use contraception\n* Adult subject to a legal protection\n* Not covered by Health insurance\n* Patient unable to understand and sign written informed consent.",{"count":247,"type":20},37,"The overall objective of this GUIDE.MRD consortium is to confirm that ctDNA detected after curative intended treatment for PDAC is a marker of residual disease and for risk-of-recurrence, and applicable in clinical practice.\n\nPrimary objective To confirm that ctDNA analyses performed after PDAC treatment can identify patients with a high risk-of-recurrence.\n\nSpecifically, the investigators want to determine the association between disease-free survival (DFS) and ctDNA detection status after\n\n1. curative-intended surgery and\n2. adjuvant chemotherapy.\n\nFRENCH.MRD.PDAC is the French study of the european GUIDE.MRD project",[250,251,26,27,56],"Pancreatic Cancer Resectable","Pancreatic Ductal Adenocarcinoma",[251,250,26,27,56],"2025-07-07",{"date":255,"type":34},"2025-07-10",{"date":257,"type":34},"2024-03-01",{"date":259,"type":20},"2028-10-31",{"name":40,"class":41},{"id":262,"slug":263,"hasResults":11,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":267,"eligibilityCriteria":268,"healthyVolunteers":269,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":270,"targetDuration":4,"studyType":76,"phases":271,"briefSummary":272,"conditions":273,"keywords":278,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":281,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":42},"100501526","liver-cancer-and-immunotherapy-in-the-liquid-biopsy-era-100501526","NCT05810402","Liver Cancer and Immunotherapy in the Liquid Biopsy Era","Liver Cancer and Immunotherapy : Clinical Relevance of LIquid BioPSY","LILIPSY","Inclusion Criteria:\n\n* Patients of at least 18 years old,\n* Patients with advanced hepatocellular carcinoma or HCC with indication for first-line PD-1 or PD-L1 immunotherapy in MDT, without prior systemic therapy,\n* The diagnosis of HCC is established according to imaging criteria (LI-RADSv2018 criteria) or after histological evidence,\n* Advanced HCC defined by BCLC stages B and C,\n* Patients with oral consent.\n\nExclusion Criteria:\n\n* Administration of a previous systemic anti-tumor treatment (immunotherapy or chemotherapy or targeted therapy)\n* No personal history of neoplasia in the previous 5 years\n* No personal history of systemic inflammatory diseases\n* No immunosuppressive treatment or treatment that could modify immunity (anti-TNF...)\n* No affiliation or non-beneficiary of a Social Security system;\n* Vulnerable persons according to article L1121-6 of the CSP ;\n* Persons of full age who are protected or unable to give their consent according to article L1121-8 of the CSP;\n* Pregnant or breastfeeding women according to article L1121-5 of the CSP.\n* Non-inclusion due to follow-up difficulties (transfer, insufficient motivation, poor compliance, priority associated pathology in care, etc.)",true,{"count":205,"type":20},[103],"The goal of this prospective clinical trial is to identify a predictive biomarker in patients with advanced HCC (stage B and C) using a combinatorial approach of the liquid biopsy.\n\nThe main questions it aims to answer are:\n\n* Is multi-omic liquid biopsy approach able to identify a strong predictive biomarker of immunotherapy efficiency?\n* Is there a correlation between tissue biopsy (PD-L1 tissue level of expression) and liquid biopsy (detection of CTC expressing PD-L1) in HCC patients?\n\nParticipants blood will be collected at several time points.",[274,275,276,277,27],"Hepatocellular Carcinoma","BCLC Stage B Hepatocellular Carcinoma","BCLC Stage C Hepatocellular Carcinoma","Immune Checkpoint Inhibitor",[274,279,277,27,280],"BCLC Stage B and C","Precision Medicine",{"date":255,"type":34},{"date":283,"type":34},"2023-06-28",{"date":285,"type":20},"2027-05",{"name":40,"class":41},{"id":288,"slug":289,"hasResults":11,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":293,"eligibilityCriteria":294,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":295,"targetDuration":296,"studyType":21,"phases":4,"briefSummary":297,"conditions":298,"keywords":302,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":42},"100511505","versatile-ampification-single-molecule-detection-in-liquid-biopsy-100511505","NCT05940311","Versatile Ampification Single-Molecule Detection in Liquid Biopsy","Versatile Ampification Method for Single-Molecule Detection in Liquid Biopsy","VerSiLiB","Inclusion Criteria:\n\n* age: ≥ 18\n* PFS≤2\n* Patients willing to sign an informed consent;\n* Confirmed (cytologically or histologically) cutaneous melanoma diagnosis\n* Confirmed BRAF p. V600E tumor status\n* Eligible for BRAFi\u002FMEKi treatment or Immune checkpoint blockade in either the adjuvant or advanced settings (the latter typically stages III\u002FIV, high risk).\n\nExclusion Criteria:\n\n* Life expectancy \\\u003C8 weeks\n* Other clinical conditions preventing blood drawing compliance, as per physician's choice.",{"count":181,"type":20},"3 Years","The trial will test a paradigm-changing in vitro diagnostic device for Liquid Biopsy enabling facile simultaneous detection of protein and nucleic acid analytes with sensitivity at single-molecule level, e.g. not achievable with any alternative technology. A novel affinity-mediated transport amplification (AMT) method will be tested allowing for the multiplexed quantification of rare biomarkers circulating in blood. The Versilib AMT photonic biosensor will test two analytes: the known actionable DNA mutation BRAF p.V600E, and a melanoma-restricted protein antigen. The results will be compared to digital PCR and ELISA methods.",[27,299,300,301],"Melanoma (Skin)","Melanoma Stage III","Melanoma Stage IV",[303],"BRAFV600E","2024-11-25",{"date":306,"type":34},"2024-11-27",{"date":308,"type":34},"2022-04-27",{"date":310,"type":20},"2026-03-31",{"name":312,"class":41},"Regina Elena Cancer Institute",{"id":314,"slug":315,"hasResults":11,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":4,"eligibilityCriteria":319,"healthyVolunteers":11,"sex":320,"minAge":4,"maxAge":4,"enrollmentInfo":321,"targetDuration":323,"studyType":21,"phases":4,"briefSummary":324,"conditions":325,"keywords":332,"overallStatus":187,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":4},"100567757","clinical-studies-of-endometrial-cytology-and-cervical-methylation-assays-in-endometrial-cancer-screening-and-fertility-preservation-evaluation-100567757","NCT06672341","Clinical Studies of Endometrial Cytology and Cervical Methylation Assays in Endometrial Cancer Screening and Fertility-Preservation Evaluation","A Prospective, Open, Observational Clinical Study on Endometrial Cytology and Cervical Methylation Testing for Screening and Evaluating Fertility-Sparing Treatment in Endometrial Cancer","Inclusion Criteria:\n\n* Participants must meet all of the following criteria to be eligible for the study:\n\n  1. Color Doppler ultrasound indicating intrauterine masses or abnormal endometrial thickening (for postmenopausal women not receiving hormone replacement therapy, endometrial thickness \\>5mm).\n  2. Patients undergoing follow-up and efficacy evaluation for fertility-sparing treatment of endometrial cancer or atypical endometrial hyperplasia.\n  3. Patients with endometrial thickening following endocrine therapy for breast cancer.\n  4. Signed informed consent form.\n  5. Good compliance.\n\nExclusion Criteria:\n\n* Participants meeting any of the following criteria will be excluded:\n\n  1. Diagnosed with cervical cancer.\n  2. Severe systemic complications preventing hysteroscopy.\n  3. Pregnant or recent history of miscarriage.\n  4. Acute genital tract infection or pelvic inflammatory disease.\n  5. Insertion of an intrauterine device.\n  6. Sexual activity, vaginal douching, or medication use within 24 hours.","FEMALE",{"count":322,"type":20},200,"1 Year","The current study aims to assess high-risk patients using both liquid-based cytology and cervical methylation testing. The results will be compared with the traditional hysteroscopic pathological findings to determine the sensitivity and specificity of these methods for early detection of endometrial cancer, thereby evaluating their potential application in early screening.\n\nPrimary Objectives：\n\n1. To evaluate the sensitivity, specificity, and accuracy of endometrial cytology for screening endometrial cancer.\n2. To assess the sensitivity, specificity, and accuracy of methylation testing for screening endometrial cancer.\n3. To perform further molecular testing on tissue samples obtained from endometrial cytology and cervical methylation tests, aiming to explore early screening-sensitive indicators.\n\nSecondary Objectives：\n\n1. To determine the value of endometrial cytology in evaluating the efficacy of fertility-sparing treatments for endometrial cancer.\n2. To assess the value of methylation testing in evaluating the efficacy of fertility-sparing treatments for endometrial cancer.",[326,327,328,329,330,27,331],"Endometrial Cancer","Methylation","Cytology","Fertility Preservation","Screening Tool","Non-invasive",[326,333,334,328,335,336,337,109,338],"screening","methylation","Liquid-Based Cytology Test","Early diagnosis","fertility-sparing","non-invasive","2024-11-03",{"date":341,"type":34},"2024-11-05",{"date":343,"type":20},"2024-11-04",{"date":345,"type":20},"2026-02-01",{"name":347,"class":41},"Yulan Ren",{"id":349,"slug":350,"hasResults":11,"nctId":351,"briefTitle":352,"officialTitle":352,"acronym":4,"eligibilityCriteria":353,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":354,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":356,"conditions":357,"keywords":363,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":369,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":375,"locationsCount":42},"100509828","observational-study-of-viral-biomarkers-and-micrornas-in-tumors-orofarynx-and-occult-tumors-positive-for-papilloma-virus-100509828","NCT05918510","Observational Study of Viral BIOmarkers and microRNAs in Tumors Orofarynx and Occult Tumors Positive for Papilloma Virus","Inclusion Criteria:\n\n* Squamous cell carcinomas of the oropharynx and occult neoplasms with lymph node metastases laterocervical cytologically positive for squamous cell carcinoma treated with TORS or RT or RT\u002FCT\n* Age \\> 18 years\n* ECOG performance status \\\u003C\\_ 2\n* Ability to follow study procedures and complete questionnaires\n* Signature of informed consent\n\nExclusion Criteria:\n\n* Presence of distant metastases at the time of diagnosis\n* Previous cancer of the head and neck district\n* Second tumor in therapy or follow-up for less than 5 years",{"count":355,"type":20},142,"Based on the evidence summarized in the introduction, the clinician hypothesize that the detection of the presence and expression of HPV-DNA, certain miRNAs, and a certain mutational profile in the tissues and biological fluids of these patients, may have important prognostic and diagnostic value not only in HPV-related OPSCCs but also in HPV+ occult T. Accordingly, this study aims to aim to better characterize their potential as biomarkers and to detect the possibility of their their use to implement the sensitivity and specificity of radiological methodologies (PET-CT and MRI), already in use in clinical practice, for monitoring disease progression in this specific subgroup. Finally, by using the collected material to generate organoids and Patient Derived Xenograft (PDX), the study also aims to identify possible new molecular drugs, which could solve the problem of resistance to radiochemotherapy.",[358,359,360,27,361,362],"Squamous Cell Carcinoma of the Oropharynx","Carcinomas of Unknown Primary Site","High-risk Human Papillomavirus Infection","Lymph Node Metastasis","Occult Tumor of the Head and Neck Area",[364,365,366,367],"Oropharyngeal Tumor","Occult Cancer","HPV Infection","head-neck area","2023-10-06",{"date":370,"type":34},"2023-10-10",{"date":372,"type":34},"2022-04-04",{"date":374,"type":20},"2029-04-04",{"name":312,"class":41},{"id":377,"slug":378,"hasResults":11,"nctId":379,"briefTitle":380,"officialTitle":381,"acronym":4,"eligibilityCriteria":382,"healthyVolunteers":269,"sex":16,"minAge":383,"maxAge":384,"enrollmentInfo":385,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":387,"conditions":388,"keywords":391,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":394,"lastUpdatePostDateStruct":395,"startDateStruct":397,"completionDateStruct":399,"leadSponsor":401,"locationsCount":66},"100516988","the-jinling-cohort-100516988","NCT06011694","The Jinling Cohort","A Prospective, Multicenter Cohort Study of the Multi-omics Liquid Biopsy MCED Test MERCURY in an Average Risk Chinese Population","Inclusion Criteria:\n\n1、45-75 years of age; 2、Willing and able to undergo blood sample collection, health questionnaires and annual routine physical exams once a year for three consecutive years; 3、Residents in Nanjing; 4、Fully understand the study and able to provide a written informed consent\n\nExclusion Criteria:\n\n1. Pregnant women;\n2. Individuals who have history of cancer or current diagnosis of cancer;\n3. Individuals who have organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant;\n4. Individulas who have blood transfusion within 30 days prior to the blood draw;\n5. Individuals who have an acute infection or inflammation within 14 days prior to the blood draw;\n6. Individuals who have taken medication with anti-tumor effects within 30 days prior to the blood draw;\n7. Individuals who will not be able to comply with the protocol procedures judged by researchers","45 Years","75 Years",{"count":386,"type":20},15000,"The Jinling Cohort is a prospective, multicenter cohort study in which 15,000 eligible individuals aged 45-75 in Nanjing China will be enrolled.",[389,390,27],"Cancer","Multi Cancer Early Screening",[392,393],"Early Detection of Cancer","MCED","2023-08-23",{"date":396,"type":34},"2023-08-25",{"date":398,"type":34},"2022-06-15",{"date":400,"type":20},"2027-05-15",{"name":402,"class":403},"Nanjing Shihejiyin Technology, Inc.","INDUSTRY",{"id":405,"slug":406,"hasResults":11,"nctId":407,"briefTitle":408,"officialTitle":409,"acronym":410,"eligibilityCriteria":411,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":412,"targetDuration":414,"studyType":21,"phases":4,"briefSummary":415,"conditions":416,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":419,"lastUpdatePostDateStruct":420,"startDateStruct":422,"completionDateStruct":424,"leadSponsor":426,"locationsCount":42},"100456267","prospective-sampling-in-driver-mutation-pulmonary-oncology-patients-on-tyrosine-kinase-inhibitors-start-tki-100456267","NCT05221372","ProSpecTive sAmpling in dRiver muTation Pulmonary Oncology Patients on Tyrosine Kinase Inhibitors (START-TKI)","proSpecTive sAmpling in dRiver muTation Pulmonary Oncology Patients on Tyrosine Kinase Inhibitors","START-TKI","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Able to understand the written informed and able to give informed consent\n* Locally advanced or metastatic NSCLC with oncogenic driver mutation\n* Treatment with TKI according to standard of care\n\nExclusion Criteria:\n\n* Unable to draw blood for study purposes",{"count":413,"type":20},1300,"10 Years","The study is perfomed with adult patients with non-small cell lung cancer treated with tyrosine kinase inhibitor. The objective is to collect repeated samples of blood from patients (starting) on a tyrosine kinase inhibitor, for liquid mutation testing, and pharmacokinetic analysis.",[417,27,418],"Non Small Cell Lung Cancer","Tyrosine Kinase Inhibitor","2022-02-02",{"date":421,"type":34},"2022-02-18",{"date":423,"type":34},"2017-02-02",{"date":425,"type":20},"2031-01-01",{"name":427,"class":41},"Erasmus Medical Center"]